5 Unrivaled Penny Stocks to Buy Now

2. X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

Number of Hedge Fund Holders: 26

Stock Price: $4.41

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) reported first-quarter revenue of $2.71 million on May 6, compared with analyst consensus estimates of $3.2 million. Management stated that its top priority remains the execution and enrollment of the pivotal Phase 3 4WARD trial evaluating mavorixafor in chronic neutropenia, with full enrollment expected by the end of the third quarter. The company also highlighted that the European Commission granted marketing authorization for XOLREMDI for patients with WHIM syndrome in the European Union. Executive Chairman Adam Craig noted that the approval reinforces the broader commercial and therapeutic potential of the company’s rare disease platform and will support future commercialization efforts through European partner Norgine.

Earlier, on April 29, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced that the European Commission had formally approved Xolremdi capsules for the treatment of patients with WHIM syndrome across the European Union. Management described the approval as an important milestone that expands access to the therapy beyond the United States while validating the company’s targeted approach to treating rare hematologic disorders. In addition to ongoing commercialization efforts, the company continues advancing its global Phase 3 trial program evaluating mavorixafor in chronic neutropenia.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a commercial-stage biopharmaceutical company focused on restoring immune system function through the development of novel therapies targeting rare diseases and hematologic disorders. Founded in 2014 and headquartered in Boston, the company develops precision medicines designed to address unmet medical needs in immunology and rare disease treatment markets.

The recent European regulatory approval and continued advancement of late-stage clinical programs could improve the company’s long-term commercial outlook and broaden global market opportunities. With 26 hedge funds maintaining exposure and shares trading near $4.41, XFOR may appeal to investors seeking biotech companies with regulatory momentum and rare disease catalysts.